Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. No abstract available.

2.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16.

3.

An experience of second-trimester anhydramnios salvaged by single amnioinfusion.

Io S, Kondoh E, Chigusa Y, Tani H, Hamanishi J, Konishi I.

J Med Ultrason (2001). 2017 Nov 20. doi: 10.1007/s10396-017-0842-1. [Epub ahead of print]

PMID:
29159576
4.

Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.

Murakami R, Matsumura N, Brown JB, Higasa K, Tsutsumi T, Kamada M, Abou-Taleb H, Hosoe Y, Kitamura S, Yamaguchi K, Abiko K, Hamanishi J, Baba T, Koshiyama M, Okuno Y, Yamada R, Matsuda F, Konishi I, Mandai M.

Am J Pathol. 2017 Oct;187(10):2246-2258. doi: 10.1016/j.ajpath.2017.06.012. Epub 2017 Sep 6.

PMID:
28888422
5.

Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.

Ohsuga T, Yamaguchi K, Kido A, Murakami R, Abiko K, Hamanishi J, Kondoh E, Baba T, Konishi I, Matsumura N.

BMC Cancer. 2017 Aug 29;17(1):580. doi: 10.1186/s12885-017-3573-1.

6.

Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma.

Inoue A, Yamaguchi K, Kurata Y, Murakami R, Abiko K, Hamanishi J, Kondoh E, Baba T, Kido A, Konishi I, Matsumura N.

J Gynecol Oncol. 2017 Sep;28(5):e62. doi: 10.3802/jgo.2017.28.e62. Epub 2017 Jun 1.

7.

Cancer immunotherapies targeting the PD-1 signaling pathway.

Iwai Y, Hamanishi J, Chamoto K, Honjo T.

J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9. Review.

8.

Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.

Koshiyama M, Matsumura N, Imai S, Yamanoi K, Abiko K, Yoshioka Y, Yamaguchi K, Hamanishi J, Baba T, Konishi I.

Med Sci Monit. 2017 Feb 15;23:826-833.

9.

Successful management of intraoperative haemorrhage during emergency cervical cerclage using balloon tamponade.

Kanbayashi S, Kondoh E, Suginami K, Io S, Hamanishi J, Konishi I.

J Obstet Gynaecol. 2017 May;37(4):523-524. doi: 10.1080/01443615.2016.1268581. Epub 2017 Jan 31. No abstract available.

PMID:
28141954
10.

Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer.

Sakae C, Yamaguchi K, Matsumura N, Nakai H, Yoshioka Y, Kondoh E, Hamanishi J, Abiko K, Koshiyama M, Baba T, Kido A, Mandai M, Konishi I.

J Gynecol Oncol. 2016 Nov;27(6):e57. doi: 10.3802/jgo.2016.27.e57. Epub 2016 Jun 29.

11.

Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.

Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, Yoshioka Y, Koshiyama M, Konishi I.

Clin Cancer Res. 2017 Jan 15;23(2):587-599. doi: 10.1158/1078-0432.CCR-16-0387. Epub 2016 Jul 11.

12.

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.

Abou-Taleb H, Yamaguchi K, Matsumura N, Murakami R, Nakai H, Higasa K, Amano Y, Abiko K, Yoshioka Y, Hamanishi J, Koshiyama M, Baba T, Yamada R, Matsuda F, Konishi I, Mandai M.

Oncotarget. 2016 Aug 23;7(34):54758-54770. doi: 10.18632/oncotarget.10181.

13.

Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.

Yamanoi K, Matsumura N, Murphy SK, Baba T, Abiko K, Hamanishi J, Yamaguchi K, Koshiyama M, Konishi I, Mandai M.

Oncotarget. 2016 Jul 26;7(30):47620-47636. doi: 10.18632/oncotarget.9951.

14.

Magnetic resonance imaging findings and prognosis of gastric-type mucinous adenocarcinoma (minimal deviation adenocarcinoma or adenoma malignum) of the uterine corpus: Two case reports.

Hino M, Yamaguchi K, Abiko K, Yoshioka Y, Hamanishi J, Kondoh E, Koshiyama M, Baba T, Matsumura N, Minamiguchi S, Kido A, Konishi I.

Mol Clin Oncol. 2016 May;4(5):699-704. Epub 2016 Feb 23.

15.

[Future Prospects of Anit-PD-1 or Anti-PD-L1 Antibody Therapy].

Hamanishi J, Mandai M, Konishi I.

Gan To Kagaku Ryoho. 2016 Feb;43(2):182-8. Japanese. No abstract available.

PMID:
27093728
16.

Immune checkpoint inhibition in ovarian cancer.

Hamanishi J, Mandai M, Konishi I.

Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7. Review.

PMID:
27055470
17.

Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity.

Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I.

Clin Cancer Res. 2016 May 15;22(10):2329-34. doi: 10.1158/1078-0432.CCR-16-0224. Epub 2016 Mar 25.

18.

Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.

Murakami R, Matsumura N, Brown JB, Wang Z, Yamaguchi K, Abiko K, Yoshioka Y, Hamanishi J, Baba T, Koshiyama M, Mandai M, Yamada R, Konishi I.

Gynecol Oncol. 2016 Apr;141(1):49-56. doi: 10.1016/j.ygyno.2016.02.027.

PMID:
27016229
19.

Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.

Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, Yamanoi K, Abiko K, Yoshioka Y, Hamanishi J, Yamaguchi K, Baba T, Koshiyama M, Enomoto T, Okamoto A, Murphy SK, Mori S, Mikami Y, Minamiguchi S, Konishi I.

Am J Pathol. 2016 May;186(5):1103-13. doi: 10.1016/j.ajpath.2015.12.029. Epub 2016 Mar 15.

PMID:
26993207
20.

Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.

Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I.

Int J Clin Oncol. 2016 Jun;21(3):456-61. doi: 10.1007/s10147-016-0968-y. Epub 2016 Mar 11. Review.

PMID:
26968587
21.

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.

Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I.

Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22. Review.

22.

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.

Abou-Taleb HA, Koshiyama M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Abiko K, Yamanoi K, Murakami R, Horikawa N, Taha AA, Kitamura S, Konishi I.

J Int Med Res. 2016 Apr;44(2):346-56. doi: 10.1177/0300060515591858. Epub 2016 Feb 1.

23.

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.

Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, Konishi I, Mandai M.

Cancer Res. 2015 Dec 1;75(23):5034-45. doi: 10.1158/0008-5472.CAN-14-3098. Epub 2015 Nov 16.

24.

Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients.

Horikawa N, Baba T, Matsumura N, Murakami R, Abiko K, Hamanishi J, Yamaguchi K, Koshiyama M, Yoshioka Y, Konishi I.

BMC Cancer. 2015 Oct 19;15:739. doi: 10.1186/s12885-015-1703-1.

25.

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I.

J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.

PMID:
26351349
26.

Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival.

Amano Y, Mandai M, Yamaguchi K, Matsumura N, Kharma B, Baba T, Abiko K, Hamanishi J, Yoshioka Y, Konishi I.

Oncotarget. 2015 Sep 22;6(28):26002-17. doi: 10.18632/oncotarget.4692.

27.

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M.

Br J Cancer. 2015 Apr 28;112(9):1501-9. doi: 10.1038/bjc.2015.101. Epub 2015 Mar 31.

28.

The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target.

Peng J, Yoshioka Y, Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Kharma B, Murakami R, Abiko K, Murphy SK, Konishi I.

Mol Carcinog. 2016 Apr;55(4):335-45. doi: 10.1002/mc.22283. Epub 2015 Feb 7.

PMID:
25663289
29.

Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta.

Nagura M, Matsumura N, Baba T, Murakami R, Kharma B, Hamanishi J, Yamaguchi K, Abiko K, Koshiyama M, Mandai M, Murata T, Murphy SK, Konishi I.

Gynecol Oncol. 2015 Jan;136(1):104-11. doi: 10.1016/j.ygyno.2014.11.075. Epub 2014 Nov 28.

PMID:
25434636
30.

Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix.

Nagura M, Koshiyama M, Matsumura N, Kido A, Baba T, Abiko K, Hamanishi J, Yamaguchi K, Mikami Y, Konishi I.

BMC Cancer. 2014 Oct 27;14:784. doi: 10.1186/1471-2407-14-784.

31.

STAT1 drives tumor progression in serous papillary endometrial cancer.

Kharma B, Baba T, Matsumura N, Kang HS, Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe Y, Yoshioka Y, Murphy SK, Mandai M, Hunstman DG, Konishi I.

Cancer Res. 2014 Nov 15;74(22):6519-30. doi: 10.1158/0008-5472.CAN-14-0847. Epub 2014 Sep 29.

32.

[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].

Hamanishi J, Konishi I.

Gan To Kagaku Ryoho. 2014 Sep;41(9):1071-6. Japanese.

PMID:
25248890
33.

Menstrual cyclic change of metastin/GPR54 in endometrium.

Baba T, Kang HS, Hosoe Y, Kharma B, Abiko K, Matsumura N, Hamanishi J, Yamaguchi K, Yoshioka Y, Koshiyama M, Mandai M, Murphy SK, Konishi I.

Med Mol Morphol. 2015 Jun;48(2):76-84. doi: 10.1007/s00795-014-0081-0. Epub 2014 Jun 8.

PMID:
24908069
34.

Recurrence of a carcinoid tumor of the ovary 13 years after the primary surgery: A case report.

Amano Y, Mandai M, Baba T, Hamanishi J, Yoshioka Y, Matsumura N, Konishi I.

Oncol Lett. 2013 Nov;6(5):1241-1244. Epub 2013 Aug 16.

35.

A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography.

Yamanoi K, Matsumura N, Kido A, Baba T, Hamanishi J, Yamaguchi K, Yoshioka Y, Abou Taleb H, Togashi K, Konishi I.

Gynecol Oncol. 2013 Dec;131(3):701-7. doi: 10.1016/j.ygyno.2013.10.014. Epub 2013 Oct 19.

36.

Transverse fundal uterine incision for delivery of extremely low birth-weight infants.

Taga A, Kondoh E, Hamanishi J, Kawasaki K, Fujita K, Mogami H, Konishi I.

J Matern Fetal Neonatal Med. 2014 Aug;27(12):1285-7. doi: 10.3109/14767058.2013.854328. Epub 2013 Nov 7.

PMID:
24111613
37.

Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.

Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, Baba T, Hamanishi J, Abiko K, Kosaka K, Murphy SK, Mori S, Konishi I.

Mol Carcinog. 2015 Jan;54(1):35-49. doi: 10.1002/mc.22072. Epub 2013 Sep 17.

PMID:
24105991
38.

Treatment decision-making for post-partum hemorrhage using dynamic contrast-enhanced computed tomography.

Kawamura Y, Kondoh E, Hamanishi J, Kawasaki K, Fujita K, Ueda A, Kawamura A, Mogami H, Konishi I.

J Obstet Gynaecol Res. 2014 Jan;40(1):67-74. doi: 10.1111/jog.12123. Epub 2013 Aug 12.

PMID:
23937115
39.

Ileal perforation and massive intestinal haemorrhage from endometriosis in pregnancy: case report and literature review.

Nishikawa A, Kondoh E, Hamanishi J, Yamaguchi K, Ueda A, Sato Y, Konishi I.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):20-4. doi: 10.1016/j.ejogrb.2013.04.018. Epub 2013 Jun 10. Review.

40.

Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.

Kharma B, Baba T, Mandai M, Matsumura N, Murphy SK, Kang HS, Yamanoi K, Hamanishi J, Yamaguchi K, Yoshioka Y, Konishi I.

Int J Cancer. 2013 Nov;133(9):2234-44. doi: 10.1002/ijc.28220. Epub 2013 May 25.

41.

PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.

Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I.

Clin Cancer Res. 2013 Mar 15;19(6):1363-74. doi: 10.1158/1078-0432.CCR-12-2199. Epub 2013 Jan 22.

42.

[Immunological aspect of metastasis of ovarian cancer].

Mandai M, Hamanishi J, Abiko K, Yoshioka Y, Konishi I.

Nihon Rinsho. 2012 Jun;70 Suppl 4:507-11. Japanese. No abstract available.

PMID:
23156299
43.

Cervical clamp with ring forceps to prevent prolapse of an intrauterine balloon in the management of postpartum hemorrhage.

Kawamura A, Kondoh E, Hamanishi J, Kawamura Y, Kusaka K, Ueda A, Kawasaki K, Fujita K, Mogami H, Konishi I.

J Obstet Gynaecol Res. 2013 Mar;39(3):733-7. doi: 10.1111/j.1447-0756.2012.02017.x. Epub 2012 Oct 29.

PMID:
23106866
44.

Pyomayoma during pregnancy: a case report and review of the literature.

Kobayashi F, Kondoh E, Hamanishi J, Kawamura Y, Tatsumi K, Konishi I.

J Obstet Gynaecol Res. 2013 Jan;39(1):383-9. doi: 10.1111/j.1447-0756.2012.01947.x. Epub 2012 Jul 29. Review.

PMID:
22845799
45.

Serial magnetic resonance imaging of placenta percreta with bladder involvement during pregnancy and postpartum: a case report.

Ueda Y, Kondoh E, Kakui K, Hamanishi J, Ueda M, Nishikawa A, Tatsumi K, Konishi I.

J Obstet Gynaecol Res. 2013 Jan;39(1):359-63. doi: 10.1111/j.1447-0756.2012.01899.x. Epub 2012 Jun 4.

PMID:
22672446
46.

The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors.

Hamanishi J, Mandai M, Abiko K, Matsumura N, Baba T, Yoshioka Y, Kosaka K, Konishi I.

Clin Immunol. 2011 Dec;141(3):338-47. doi: 10.1016/j.clim.2011.08.013. Epub 2011 Sep 2.

47.

Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype.

Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Konishi I.

Cancer Lett. 2011 Nov 28;310(2):129-33. doi: 10.1016/j.canlet.2011.06.039. Epub 2011 Jul 8. Review.

PMID:
21802200
48.

Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells.

Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Yoshioka Y, Konishi I.

Horm Cancer. 2010 Dec;1(6):291-6. doi: 10.1007/s12672-010-0046-2.

PMID:
21761360
49.

The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.

Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, Konishi I.

Int J Cancer. 2012 Jan 1;130(1):20-8. doi: 10.1002/ijc.25961. Epub 2011 Apr 18.

50.

GPR54 is a target for suppression of metastasis in endometrial cancer.

Kang HS, Baba T, Mandai M, Matsumura N, Hamanishi J, Kharma B, Kondoh E, Yoshioka Y, Oishi S, Fujii N, Murphy SK, Konishi I.

Mol Cancer Ther. 2011 Apr;10(4):580-90. doi: 10.1158/1535-7163.MCT-10-0763. Epub 2011 Jan 31.

Supplemental Content

Loading ...
Support Center